Inovio Pharmaceuticals, Inc.
A maker of DNA-based vaccines and medicines that teach the body's own cells to fight disease. The company designs synthetic DNA instructions and delivers them with its hand-held CELLECTRA device, whose brief electrical pulses open tiny pores in cells to target cancers and HPV-related conditions. Founded in 1983 as Biotechnologies & Experimental Research, it later operated as Genetronics and took its current name after acquiring the Norwegian gene-delivery firm Inovio in 2005.
Granted 46.0K
Granted 10.8K
Granted 13.5K
Granted 16.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Shea Jacqueline ElizabethChief Executive Officer, Director · 4 transactions | +58% | 111.0K | 46.0K | — | — |
| Humeau LaurentChief Scientific Officer · 4 transactions | +14.1% | 49.0K | 10.8K | — | — |
| Kies PeterCFO · 4 transactions | +29.4% | 47.9K | 13.5K | — | — |
| Sumner Michael JohnChief Medical Officer · 6 transactions | +83.9% | 42.0K | 16.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.